Table 2

Rituximab maintenance versus retreatment: comparison of efficacy

Maintenance

Retreatment

P


Overall response rate (%)

52%

35%

0.14

Complete response rate (%)

27%

4%

0.007

% in continuous remission

45%

24%

0.05

% remaining in continuous remission

23%

2%

0.03

Median progression-free survival (months)

31.7

7.4

0.007

Median duration of rituximab benefit (months)

31.7

27.4

0.94


Mohrbacher Arthritis Research & Therapy 2005 7(Suppl 3):S19-S25   doi:10.1186/ar1739